Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 4/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14371764 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3PREPPTPN1 | |
| SCHEMBL14371753 | 0.88 | CHRM2 (0.38) | CHRM2CHRM1CHRM3PREPPTPN1 | |
| SCHEMBL6120856 | 0.87 | CHRM2 (0.42) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL6120851 | 0.87 | CHRM2 (0.42) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL14371765 | 0.87 | CHRM2 (0.42) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL24894476 | 0.87 | CHRM2 (0.42) | CHRM2CHRM1CHRM3PREPPTPN1 | |
| SCHEMBL5368239 | 0.87 | CHRM2 (0.42) | CHRM2CHRM1CHRM3PREPPTPN1 | |
| SCHEMBL24894315 | 0.87 | CHRM2 (0.42) | CHRM2CHRM1CHRM3PREPPTPN1 | |
| SCHEMBL5369803 | 0.87 | CHRM2 (0.42) | CHRM2CHRM1CHRM3PREPPTPN1 | |
| SCHEMBL5160118 | 0.87 | CHRM2 (0.42) | CHRM2CHRM1CHRM3PREPPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4631948-A1 | NOVEL TRICYCLIC COMPOUND AS KRAS G12D INHIBITOR, AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2025-10-15 | — | — | EP | disclosed |
| US-20240287100-A1 | ALKYLIDENE DERIVATIVES AS KRAS INHIBITORS | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| WO-2024138486-A1 | TETRACYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024123102-A1 | NOVEL TRICYCLIC COMPOUND AS KRAS G12D INHIBITOR, AND USE THEREOF | 에스케이바이오팜 주식회사 | 2024-06-13 | — | — | WO | disclosed |
| CN-117980310-A | Alkylene derivatives as KRAS inhibitors | 尼坎治疗公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2024091409-A1 | TRICYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024091409-A1 | TRICYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024051721-A1 | TETRACYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023284730-A1 | ALKYLIDENE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023284730-A1 | ALKYLIDENE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287100-A1 | ALKYLIDENE DERIVATIVES AS KRAS INHIBITORS | KRAS, NRAS, HRAS | CHRM2 4877/4885CHRM1 4880/4885CHRM3 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.